These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33583251)

  • 61. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.
    Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M
    Haematologica; 2001 Apr; 86(4):399-403. PubMed ID: 11325646
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
    Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Thalidomide in patients with advanced multiple myeloma.
    Yakoub-Agha I; Moreau P; Leyvraz S; Berthou C; Payen C; Dumontet C; Grosbois B; Beris P; Duguet C; Attal M; Harousseau JL; Facon T;
    Hematol J; 2000; 1(3):186-9. PubMed ID: 11920188
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Attainment of a stringent complete response in multiple myeloma with thalidomide monotherapy.
    Aritaka N; Ichikawa K; Nakamura H; Yasuda H; Ogura K; Matsumoto T; Komatsu N; Hirano T
    Intern Med; 2012; 51(19):2781-3. PubMed ID: 23037474
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
    Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
    Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oral therapy adherence and satisfaction in patients with multiple myeloma.
    Solano M; Daguindau E; Faure C; Loriod P; Pain C; Maes AC; Marguet P; Kroemer M; Rumpler A; Fontan J; Deconinck E; Limat S; Clairet AL
    Ann Hematol; 2021 Jul; 100(7):1803-1813. PubMed ID: 33938996
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
    Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
    Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Pomalidomide for multiple myeloma].
    Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
    Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.
    Andersen NF; Vogel U; Klausen TW; Gimsing P; Gregersen H; Abildgaard N; Vangsted AJ
    Int J Cancer; 2012 Sep; 131(5):E636-42. PubMed ID: 22139971
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
    Luo J; Gagne JJ; Landon J; Avorn J; Kesselheim AS
    Eur J Cancer; 2017 Jan; 70():22-33. PubMed ID: 27866096
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study.
    Michetti P; Weinman J; Mrowietz U; Smolen J; Peyrin-Biroulet L; Louis E; Schremmer D; Tundia N; Nurwakagari P; Selenko-Gebauer N
    Adv Ther; 2017 Jan; 34(1):91-108. PubMed ID: 27854054
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
    Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
    Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
    Lee C; Grigorian M; Nolan R; Binder G; Rice G
    J Med Econ; 2016; 19(4):397-402. PubMed ID: 26652728
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: a cross-sectional study in Southern Brazil.
    Pinheiro CA; de-Carvalho-Leite JC; Drachler ML; Silveira VL
    Braz J Med Biol Res; 2002 Oct; 35(10):1173-81. PubMed ID: 12424490
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
    Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical use and control of the dispensing of thalidomide in Brasilia-Federal District, Brazil, from 2001 to 2012.
    Paumgartten FJ; de Souza NR
    Cien Saude Colet; 2013 Nov; 18(11):3401-8. PubMed ID: 24196904
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up.
    Vasquez J; Ruiz R; Aliaga K; Valencia F; Villena M; Quintana S; Vidaurre T; Casanova L
    JCO Glob Oncol; 2021 Jul; 7():1199-1205. PubMed ID: 34297605
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
    Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R
    J Clin Oncol; 2003 Jan; 21(1):16-9. PubMed ID: 12506164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.